|
|
|
| Research progress of Gemcitabine in combined therapy of pancreatic cancer |
| SHI Xueying ZHAO Jin |
| Department of General Surgery, Baogang Hospital of Inner Mongolia, Inner Mongolia Autonomous Region, Baotou 014010, China |
|
|
|
Abstract Pancreatic cancer is one of the most aggressive tumors at present. Because of its occult incidence, most patients have been diagnosed as advanced stage and lost the opportunity of operation. Therefore, chemotherapy has become the main treatment for advanced pancreatic cancer. Gemcitabine has become the first-line chemotherapy drug for pancreatic cancer because of its unique mechanism, low toxicity, and no cross resistance when combined with other chemotherapy drugs. Due to the limited efficacy of Gemcitabine alone, and the problems of large dose use of side effects and drug resistance, domestic and foreign scholars continue to explore the combination of Gemcitabine and Gemcitabine nano carrier drug delivery technology for improving the survival period and quality of life of patients with pancreatic cancer.
|
|
|
|
|
|
[1] 陈煜.吉西他滨与多西他赛对老年晚期非小细胞肺癌的治疗效果分析[J].中外医学研究，2019，17（12）：11-13.
[2] 王大志，陈娜，郭成业.GP与TP方案治疗晚期老年非小细胞肺癌的临床对比研究[J].中国医药指南，2014，12（21）：134-136.
[3] Kamisawa T，Wood LD，Itoi T，et al. Pancreatic cancer [J]. Lancet，2016，388（10039）：73-85.
[4] Parhi P，Mohanty C，Sahoo SK. Nanotechnology-based combinational drug delivery： an emerging approach for cancer therapy [J]． Drug Discov Today，2012，17（17/18）：1044-1052．
[5] 罗芳，王丹，夏桂民.抗癌药物吉西他滨纳米递送系统研究进展[J].中国医药生物技术，2019，14（1）：83-88.
[6] 张彩霞，林能明.吉西他滨药代动力学研究进展[J].肿瘤学杂志，2004，10（4）：271-274.
[7] 谢燕鸣，王连心，王永炎．临床联合用药机制研究探讨[J].中国中药杂志，2014，39（18）：3424-3426．
[8] Maksimenko A，Caron J，Mougin J，et al. Gemcitabine based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies [J]. Int J Pharm，2015， 482（1/2）：38-46.
[9] 王琳，秦叔逵，邵志坚.吉西他滨治疗晚期癌症[J].南京军医学院学报，2002，24（2）：144-145.
[10] 石海峰，金征宇，周智强，等.经动脉灌注盐酸盐酸吉西他滨和5-氟尿嘧啶治疗中晚期胰腺癌的疗效分析[J].中华放射学杂志，2002，36（12）：1072-1074.
[11] 束永前，刘凌翔，黄普文，等.盐酸吉西他滨联合顺铂或氟尿嘧啶治疗晚期胰腺癌临床疗效的比较[J].实用癌症杂志，2003（5）：527-530.
[12] 丁昂，童赛雄，靳大勇，等.125Ⅰ粒子和125Ⅰ+盐酸吉西他滨在治疗局部进展期胰腺癌中的比较[J].肝胆胰外科杂志，2004（1）：19-22.
[13] Sahoo RK，Kumar L. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer [J]. N Engl J Med，2014，370（5）：479．
[14] Goldenstein D，El-Maraghi RH，Hammel P，et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer：long-term survival from a phase Ⅲ trial [J]． J Natl Cancer Inst，2015，107（2）：dju413．
[15] 梁延波.胰腺癌新辅助治疗的现状与展望[J].临床肝胆病杂志，2019，35（5）：946-952.
[16] 刘元芬，周咏梅.紫杉醇与吉西他滨联合抗肿瘤作用机制及共载给药系统的研究进展[J].中国新药杂志，2019， 28（9）：1081-1086.
[17] Takahata T，Sato A，Yu C，et al. Retrospective Analysis of Weekly Paclitaxel Chemotherapy for Gemcitabine-and S-1-Resistant Pancreatic Cancer [J]. Gan To Kagaku Ryoho，2018，45（5）：817-821.
[18] 刘芸云.吉西他滨+替吉奥共同治疗晚期胰腺癌的临床分析[J].临床医药文献电子杂志，2019，6（39）：64.
[19] 张波，张娜.纳米载体共递送化疗药物用于肿瘤联合治疗的研究进展[J]．中国新药杂志，2014，23（21）：2514-2520.
[20] Poon C，He C，Liu D，et al. Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer [J]. Control Release，2015，201：90-99.
[21] Saneja A，Dubey RD，Alam N，et al. Co-formulation of p-glycoprotein substrate and inhibitor in nanocarriers： an emerging strategy for cancer chemotherapy [J]. Curr Cancer Drug Targets，2014，14（5）：419-433.
[22] Zhao X，Li F，Li Y，et al. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nan-oparticles for effective treatment of pancreatic cancer [J]. Biomaterials，2015，46：13-25.
[23] Du L，Wang-Gillam A. Trends in neoadjuvant approaches in pancreatic cancer [J]. J Natl Compr Canc Netw，2017，15（8）：1070-1077.
[24] Heinrich S，Pestalozzi BC，Schäfer M，et al. Prospective phase Ⅱ trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head [J]. J Clin Oncol，2008，26（15）：2526-2531．
[25] de Geus SW，Eskander MF，Bliss LA，et al. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma A nationwide propensity score matched analysis [J]. Surgery，2017，161（3）：592-601. |
|
|
|
